Optimizing chair time in infusion centers using intravenous cetirizine premedication for the prevention of hypersensitivity infusion reactions.

• DOI: 10.1200/jco.2021.39.15_suppl.e13508
• Publication Date: 2021-06-02T13:56:05Z
• Authors: Julio Antonio Peg...; Ahmed Ayad; Stacia Young-Wese...; Teresa Yang; Janine North; Nancy Joseph-Ridge
• Keywords: Cetirizine; Premedication

e13508 Background: Oncology infusion centers are increasingly focused on improving operational efficiencies and patient satisfaction, while maintaining quality care. One key component is optimizing chair time, which has been especially important for safety during the COVID-19 pandemic to reduce risk of transmission. Many infusions require antihistamine premedication hypersensitivity reactions (IRs). The two IV options diphenhydramine cetirizine, have a quicker onset than oral can be administered push. In treating acute urticaria, cetirizine was shown comparable diphenhydramine, with fewer side effects, it may effective preventing IRs improved time. Methods: A randomized, double-blind phase 2 study evaluating single dose 10 mg versus 50 conducted in 34 patients receiving paclitaxel, rituximab, its biosimilar or obinutuzumab (first cycle, retreatment after 6 months persistent IRs). primary objective incidence premedication. Secondary endpoints included sedation due antihistamines time readiness discharge. Sedation reported by scale 0-4 (0 = none 4 extremely severe). No formal statistical analyses were planned given exploratory nature study. Results: Adults primarily cancer (n 31 [91%]) enrolled pandemic, from March 25 November 23, 2020. median age 65 67 years groups, respectively. number 2/17 (11.8%) 3/17 (17.6%) diphenhydramine. mean score group compared lower at all points, including discharge (0.1 vs 0.4, respectively). Mean 24 minutes less (4.3 hours [1.5]) (4.7 [1.2]). This difference greater (30 less) those ≥65 (4.4 [1.3] 4.9 [1.0] hours). Regardless whether received paclitaxel 9) an anti-CD20 25), had when premedicated cetirizine. There treatment-related adverse events (AEs) (2 events) (4 events). Conclusions: first controlled trial It that prevent IRs, sedation, related AEs reduced improves center operations experience. Clinical information: NCT04189588.